$ORIC

ORIC Pharmaceuticals (ORIC) partnered with Cancer Research UK to advance ORIC-259, a potential first-in-class CIP2A-targeted therapy, into clinical development. Cancer Research UK will fund and execute early clinical trials, while ORIC retains an option to reacquire rights post-Phase 1/2 data. ORIC-259 targets CIP2A, a protein linked to cancer progression, with promising preclinical data showing antitumor activity in HRD cancers.

ORIC Pharmaceuticals (ORIC) reported Q2 results, launching a Phase 3 trial for its prostate cancer drug rinzimetostat. The company has $387.6M in cash, funding operations into 2028. R&D costs rose to $36.3M, widening net loss to $41.5M. ORIC also advanced its lung cancer program enozertinib, with data expected later this year.

Piscitelli Dominic (Chief Financial Officer) sold 77,000 shares of Oric Pharmaceuticals, Inc. (ORIC) at $13.69 ($1.05M total) on 2026-08-26 under a Rule 10b5-1 trading plan.

Oric Pharmaceuticals, Inc. (ORIC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ORIC ® Pharmaceuticals Reports Second Quarter 2026 Financial Results and Operational Updates Initiated Himalayas-1 global Phase 3 trial in patients with mCRPC previously treated with abiraterone Entered into a clinical trial collaboration and supply agreement with Ba

Oric Pharmaceuticals, Inc. (ORIC) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Effective July 28, 2026, the Board of Directors (the “Board”) of ORIC Pharmaceuticals, Inc. (the “Company”) approved the OR

JPMorgan analyst Anupam Rama named BridgeBio (BBIO), ORIC (ORIC) and Olema (OLMA) as top US SMid biotech picks, citing near-term catalysts and valuation. For BBIO, JPMorgan targets mid-$8–$9 on Attruby momentum and pipeline approvals; for ORIC, it highlights rinzimetostat dose-optimization and expects MEVPRO-1 data in 2H 2026; for OLMA, it points to fall OPERA-01 palazestrant readout.

Oric Pharmaceuticals, Inc. (ORIC) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 d103876dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 ORIC PHARMACEUTICALS, INC. 2020 EQUITY INCENTIVE PLAN (as amended and restated effective as of June 18, 2026) 1. Purposes of the Plan . The purposes of this Plan are: • to attract and retain the best available personnel for

ORIC Pharmaceuticals announced inducement grants to four new non-executive employees, comprising 216,000 non-qualified stock options and 35,000 restricted stock units. These grants, approved by ORIC's Compensation Committee, are subject to vesting schedules and continued employment, and were made in accordance with Nasdaq Rule 5635(c)(4). ORIC Pharmaceuticals is a clinical-stage oncology company focused on developing treatments for therapeutic resistance.

ORIC Pharmaceuticals announced it is advancing rinzimetostat (ORIC-944) to Phase 3 at a 400 mg once-daily dose in combination with darolutamide for metastatic castration-resistant prostate cancer, based on favorable efficacy and a differentiated safety profile from Phase 1b optimization data. The company reported strong PSA responses and a good tolerability profile at this dose, with fewer adverse events and dose modifications compared to higher doses or competitor regimens. ORIC also updated its financial position, showing approximately $412 million in cash and investments, providing a cash runway into the second half of 2028, sufficient to execute planned registrational trials for rinzimetostat and another late-stage candidate, enozertinib.

ArrowMark Colorado Holdings LLC recently reduced its stake in Oric Pharmaceuticals (NASDAQ:ORIC) by 14.2% in the third quarter, selling 180,957 shares and retaining over 1 million shares valued at approximately $13.17 million. This move comes as company insiders have also been net sellers, with CEO Jacob Chacko and another insider selling shares totaling over $1.20 million in the past three months. Despite insider selling, analysts maintain a "Moderate Buy" consensus and a price target of $20.20 for ORIC, which is currently trading around $11.90.